Programme

Plenary lecture synopses

The latent HIV-1 reservoir

November 7, 2019

08:30 - 09:00

 

Combination antiretroviral therapy (cART) induces durable suppression of virus replication but viremia invariably rebounds after treatment interruption, demonstrating that cART is not curative. One of the main mechanisms by which HIV persists is attributed to the ability of the virus to establish a latent reservoir. The recent advances in the understanding of HIV latency, in the identification of HIV cell reservoir regulation of the immune response and development of broadly neutralizing antibodies have provided the scientific rationale to explore alternative strategies aiming to achieve durable suppression of viremia in the absence of cART, so-called ‘HIV cure’. In this context, this session will focus on the recent advances in the latent HIV reservoir field and on the various strategies currently being explored to achieve an HIV cure.

 

Speaker: Matthieu Perreau, Lausanne University Hospital, Switzerland

New drugs - Who would need them?

November 7, 2019

09:00 - 09:30


In 2019, antiretroviral strategies are focused on delivering efficacy together with safety and convenience. New agents in the pipeline work at almost every conceivable point in the HIV cycle and will allow longer acting formulations and a move away from exclusively oral formulations. Additionally, there is increasing evidence in favour of two-drug regimens as a way of limiting toxicity. Who will benefit from these new drugs and strategies?

 

Speaker: Chloe Orkin, Queen Mary University of London, United Kingdom

Precision medicine in HIV

November 8, 2019

08:30 - 09:00


HIV medicine has a tradition of standardised care, long-term follow up data collection, large human cohorts, and shared criteria for the evaluation of clinical trial outcomes. These characteristics constitute a logical ground for the deployment of machine learning and deep learning tools (artificial intelligence, AI).
In this presentation, I will describe the key aspects of AI, the conditions for usability, and the basis for data access and protection. The goal of the presentation is to allow the audience to reach an informed opinion on the value and promise of AI for medicine in general and HIV care and research in particular.

 

Speaker: Amalio Telenti, The Scripps Research Institute, United States

Whole genome sequencing for tuberculosis treatment and control: A game changer?

November 8, 2019

09:00 - 09:30

Tuberculosis is, together with AIDS, the most deadly infectious disease in the world. As for other diseases, genome sequencing technologies are mature enough to make a leap forward to routine TB care, surveillance and control. However, the question about how disruptive this new technology for TB is is still debated. I will review current evidence, including research from my laboratory, showing how transformative genome sequencing has been, and likely will be, in TB. I will also highlight current pitfalls and challenges for the future including programmatic implementation and integration in the diagnostic environment.


Speaker: Iñaki Comas, Biomedicine Institute of Valencia, Spain


Registration

Registration is open

Second Announcement

Take a look

Call for abstracts

Submissions are closed